Ritter Pharmaceuticals Inc. (NASDAQ: RTTR) Attends 31st Annual ROTH Conference
Ritter Pharmaceuticals (NASDAQ: RTTR) develops innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The company’s lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 is in phase 3 clinical development with its first phase 3 clinical trial, known as “Liberatus,” currently underway. The company is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including gastrointestinal diseases, cancer, metabolic, and liver disease. For more information, visit the company's website at www.RitterPharma.com. About NetworkNewsWire NetworkNewsWire…







